Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct. / Céspedes, Nora; Jiménez, Eliécer; Lopez-Perez, Mary; Rubiano, Kelly; Felger, Ingrid; Alonso, Pedro; Arévalo-Herrera, Myriam; Corradin, Giampietro; Herrera, Sócrates.
I: Vaccine, Bind 32, Nr. 26, 30.05.2014, s. 3179-86.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct
AU - Céspedes, Nora
AU - Jiménez, Eliécer
AU - Lopez-Perez, Mary
AU - Rubiano, Kelly
AU - Felger, Ingrid
AU - Alonso, Pedro
AU - Arévalo-Herrera, Myriam
AU - Corradin, Giampietro
AU - Herrera, Sócrates
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2014/5/30
Y1 - 2014/5/30
N2 - BACKGROUND: The circumsporozoite (CS) protein is a major malaria sporozoite surface antigen currently being considered as vaccine candidate. Plasmodium vivax CS (PvCS) protein comprises a dimorphic central repeat fragment flanked by conserved regions that contain functional domains involved in parasite invasion of host cells. The protein amino (N-terminal) flank has a cleavage region (region I), essential for proteolytic processing prior to parasite invasion of liver cells.METHODS: We have developed a 131-mer long synthetic polypeptide (LSP) named PvNR1R2 that includes the N-terminal flank and the two natural repeat variant regions known as VK210 and VK247. We studied the natural immune response to this region in human sera from different malaria-endemic areas and its immunogenicity in mice.RESULTS: PvNR1R2 was more frequently recognized by sera from Papua New Guinea (PNG) (83%) than by samples from Colombia (24%) when tested by ELISA. The polypeptide formulated in Montanide ISA51 adjuvant elicited strong antibody responses in both C3H and CB6F1 mice strains. Antibodies from immunized mice as well as affinity-purified human IgG reacted with native protein by IFA test. Moreover, mouse immune sera induced strong (90%) in vitro inhibition of sporozoite invasion (ISI) of hepatoma cell lines.CONCLUSIONS: These results encourage further studies in non-human primates to confirm the elicitation of sporozoite invasion blocking antibodies, to assess cell mediated immune responses and the protective efficacy of this polypeptide.
AB - BACKGROUND: The circumsporozoite (CS) protein is a major malaria sporozoite surface antigen currently being considered as vaccine candidate. Plasmodium vivax CS (PvCS) protein comprises a dimorphic central repeat fragment flanked by conserved regions that contain functional domains involved in parasite invasion of host cells. The protein amino (N-terminal) flank has a cleavage region (region I), essential for proteolytic processing prior to parasite invasion of liver cells.METHODS: We have developed a 131-mer long synthetic polypeptide (LSP) named PvNR1R2 that includes the N-terminal flank and the two natural repeat variant regions known as VK210 and VK247. We studied the natural immune response to this region in human sera from different malaria-endemic areas and its immunogenicity in mice.RESULTS: PvNR1R2 was more frequently recognized by sera from Papua New Guinea (PNG) (83%) than by samples from Colombia (24%) when tested by ELISA. The polypeptide formulated in Montanide ISA51 adjuvant elicited strong antibody responses in both C3H and CB6F1 mice strains. Antibodies from immunized mice as well as affinity-purified human IgG reacted with native protein by IFA test. Moreover, mouse immune sera induced strong (90%) in vitro inhibition of sporozoite invasion (ISI) of hepatoma cell lines.CONCLUSIONS: These results encourage further studies in non-human primates to confirm the elicitation of sporozoite invasion blocking antibodies, to assess cell mediated immune responses and the protective efficacy of this polypeptide.
KW - Adjuvants, Immunologic
KW - Amino Acid Sequence
KW - Animals
KW - Antibodies, Protozoan
KW - Antigens, Protozoan
KW - Cell Line, Tumor
KW - Humans
KW - Immune Sera
KW - Immunity, Humoral
KW - Malaria Vaccines
KW - Malaria, Vivax
KW - Mice, Inbred C3H
KW - Molecular Sequence Data
KW - Plasmodium vivax
KW - Protozoan Proteins
KW - Vaccines, Synthetic
KW - Journal Article
KW - Research Support, N.I.H., Extramural
KW - Research Support, Non-U.S. Gov't
U2 - 10.1016/j.vaccine.2014.04.007
DO - 10.1016/j.vaccine.2014.04.007
M3 - Journal article
C2 - 24731811
VL - 32
SP - 3179
EP - 3186
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 26
ER -
ID: 169006474